Jazz Pharmaceuticals plc

JAZZ

$169.52

+48.5% (1 year change)

Market Cap

$9.71 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$107.59 - $189.00

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

18.73x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $9.71 Billion
Enterprise Value $9.37 Billion
Dividend Yield $0.00 (0.0%)
1 Year Return +48.5%
52-Week High $189.00
52-Week Low $107.59
Beta 0.72
Outstanding Shares 56.9 Million
Avg 30 Day Volume 494 Thousand

Valuation

P/E Ratio 18.73
PEG -10.57
Earnings per Share $9.07
Price to Sales Ratio 4.04
Price to Book Ratio 2.57
Revenue to Enterprise Value 3.85
EBIT to Enterprise Value 12.02
Total Debt to Enterprise Value 0.22
Debt to Equity 0.55

Profitability

Revenue $2.44 Billion
Gross Profit $2.28 Billion
EBIT $780 Million
Net Income $518 Million
Profit Margin 21.27%
Quarterly Earnings Growth (YoY) -177.2%
Return on Equity 13.65%
Return on Assets 7.67%
Return on Invested Capital 12.99%

Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration approved drug Xyrem , the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid . In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea . In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.

News

Baylor guard Jared Butler impressed Jazz brass on the court  and off

Baylor guard Jared Butler impressed Jazz brass on the court and off

Baylor guard Jared Butler (12) celebrates with teammate Adam Flagler during Final Four game against Gonzaga at Lucas Oil Stadium in Indianapolis. | Darron Cummings, Associated Press Jazz GM Justin ...

Deseret Deseret, about 16 hours ago
Careem to connect its merchants and employees through Jazz''s communications solutions *

Careem to connect its merchants and employees through Jazz''s communications solutions *

No summary available.

UrduPoint UrduPoint, 2 days ago
AdvisorShares Investments LLC Buys Invesco S&P 500 Equal Weight ETF, Invesco S&P 500 ...

AdvisorShares Investments LLC Buys Invesco S&P 500 Equal Weight ETF, Invesco S&P 500 ...

Related Stocks: TLRY , TLRY , HYFM , HEI , AGZ , CHUY , RSP , RPV , JAZZ , ARES , APO , KKR , ZYNE , ARNA , DKNG , CZR , CMG , PENN , JKH , JKK , TLRY , TLRY , MTUM , GWPH ,

GuruFocus GuruFocus, 4 days ago